131 filings
Page 3 of 7
8-K
n28te0y2z1i6si8
1 Oct 20
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
4:38pm
8-K
0prm cnla
11 Sep 20
Entry into a Material Definitive Agreement
4:47pm
8-K
vjtxtmwg9 do734
10 Sep 20
Termination of a Material Definitive Agreement
4:02pm
8-K
f5ucsx63zqcc9
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
8-K
u73f6y 49r
9 Sep 20
Intra-Cellular Therapies Announces Positive Topline Results
7:13am
8-K
9w9 8dnoo73a
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
xqu16rf78rgc
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am
8-K
jwablc vzq
28 May 20
Departure of Directors or Certain Officers
4:16pm
8-K
j8itxyir
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
qg8smfmt9 jm6hrh4
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
eevf08gcrb4 g3
2 Mar 20
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2019 Financial Results and Provides Corporate Update
7:43am
8-K
lhmx9 f4hk
8 Jan 20
Entry into a Material Definitive Agreement
5:12pm
8-K
74qiv 2cz4
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
8-K
97shm7dqmkg94rqwr0
23 Dec 19
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
8:15am
8-K
qhknt78ynskj941nett
5 Nov 19
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
7:40am
8-K
wpse9o6
10 Sep 19
Intra-Cellular Therapies Provides Lumateperone Regulatory Update
7:39am
8-K
2mxtxvm ngehtd8z
7 Aug 19
Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results
8:08am
8-K
ul00frbc bj08ciqoi
5 Aug 19
Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA
7:37am
8-K
xatqzhxd1k
24 Jul 19
Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia
6:07am
8-K
f6fa5choi supza
8 Jul 19
Intra-Cellular Therapies Announces PositiveTop-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
7:10am